FDA Approves Edarbi for High Blood Pressure

FDA News and Approvals

Author: U.S. Food and Drug Administration
Published: 2011/02/26 - Updated: 2022/05/22
Contents: Summary - Introduction - Main - Related

Synopsis: Data from clinical studies showed Edarbi tablets (azilsartan medoxomil) to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs. Edarbi is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. Adverse reactions reported by patients taking Edarbi in clinical trials were similar to those reported by those taking an inactive drug (placebo). Edarbi will be available in 80 milligrams and 40 mg doses, with the recommended dose set at 80 mg once daily. The 40 mg dose will be available for patients who are treated with high-dose diuretics taken to reduce salt in the body.

Introduction

The U.S. Food and Drug Administration has approved Edarbi tablets (azilsartan medoxomil) to treat high blood pressure (hypertension) in adults.

Main Digest

Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs, Diovan (valsartan) and Benicar (olmesartan).

"High blood pressure is often called the 'silent killer' because it usually has no symptoms until it causes damage to the body," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Drug Products in the FDA's Center for Drug Evaluation and Research. "High blood pressure remains inadequately controlled in many people diagnosed with the condition, so having a variety of treatment options is important."

Edarbi will be available in 80 milligrams and 40 mg doses, with the recommended dose set at 80 mg once daily. The 40 mg dose will be available for patients who are treated with high-dose diuretics taken to reduce salt in the body.

Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps. If blood pressure rises and stays high over time, it can damage the body in many ways. Nearly 1 in 3 adults in the United States has high blood pressure, which increases the risks of stroke, heart failure, heart attack, kidney failure, and death.

Edarbi is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.

Adverse reactions reported by patients taking Edarbi in clinical trials were similar to those reported by those taking an inactive drug (placebo).

Edarbi has a boxed warning that says the use of the drug should be avoided in pregnant women because use of the drug during the second or third trimester can cause injury and even death in the developing fetus. If a woman becomes pregnant while using the drug, it should be discontinued as soon as possible.

Edarbi is made by Takeda Pharmaceutical North America of Deerfield, Ill.

Attribution/Source(s):

This quality-reviewed publication was selected for publishing by the editors of Disabled World due to its significant relevance to the disability community. Originally authored by U.S. Food and Drug Administration, and published on 2011/02/26 (Edit Update: 2022/05/22), the content may have been edited for style, clarity, or brevity. For further details or clarifications, U.S. Food and Drug Administration can be contacted at fda.gov. NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Related Publications

Share This Information To:
𝕏.com Facebook Reddit

Page Information, Citing and Disclaimer

Disabled World is an independent disability community founded in 2004 to provide news and information to people with disabilities, seniors, their family and carers. We'd love for you to follow and connect with us on social media!

Cite This Page (APA): U.S. Food and Drug Administration. (2011, February 26 - Last revised: 2022, May 22). FDA Approves Edarbi for High Blood Pressure. Disabled World. Retrieved July 13, 2024 from www.disabled-world.com/medical/pharmaceutical/fda/edarbi.php

Permalink: <a href="https://www.disabled-world.com/medical/pharmaceutical/fda/edarbi.php">FDA Approves Edarbi for High Blood Pressure</a>: Data from clinical studies showed Edarbi tablets (azilsartan medoxomil) to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.